Synthetic Biologics Quote - SYN

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Current Price

1.02

Bid

Ask

Volume

0.00 Day's Range 0.00

0.00 52 Week Range 0.00

Market Cap

17.384M

Previous Close

1.02

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

Shares Outstanding

17,043,000

Dividend Yield

PE Ratio

-1.11

Earnings Per Share (EPS)

-1.08

Revenue

Net Profit

-18.35M

Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbio... Synthetic Biologics is a late-stage biotechnology company focused on developing gut microbiome therapeutics. Its portfolio includes SYN-010, which is intended to treat the underlying causes of irritable bowel syndrome with constipation; and SYN-004 (ribaxamase), which aims to defend the gut microbiome from the effects of regularly used intravenous drugs for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antibiotic-resistant organisms. The company is also developing monoclonal antibody therapies for the treatment of pertussis and novel discovery stage biotherapeutics for the treatment of phenylketonuria. Show more

Sector

Pharmaceutical Preparations

Industry

Business Services

Website

www.syntheticbiologics.com

Headquarters

Rockville, Maryland, USA

Founded

1993

Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference

Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference PR Newswire ROCKVILLE, Md., Feb. 9, 2022 ROCKVILLE, Md., Feb. 9, 2022 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE...

Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA

Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA Follows recent announcement of planned acquisition of VCN Biosciences...

Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022

Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022 PR Newswire ROCKVILLE, Md., Jan. 26, 2022 ROCKVILLE, Md., Jan. 26, 2022 /PRNewswire/ -- Synthetic...

Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors

Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors Lead drug candidate...

Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET

Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET Initiated a Phase 1 Multiple Ascending Dose Clinical...

Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021

Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021 -- Conference Call Scheduled for Wednesday, November 3, 2021 at 4:30 p.m. ET...

Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase

Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase Topline Data Readout Expected in Q2 2022 Phase 1 Clinical...

Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum The Company Encourages All Shareholders of Record Who Have Not Yet Voted to Do So by...

Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum PR Newswire ROCKVILLE, Md., Sept. 21, 2021 ROCKVILLE, Md., Sept. 21, 2021 /PRNewswire/...

Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET

Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET Phase 1 Single-Ascending Dose Clinical Trial of...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

SYN - Frequently Asked Questions (FAQ)

What is the current Synthetic Biologics share price?

The current share price of Synthetic Biologics is US$ 1.02

How many Synthetic Biologics shares are in issue?

Synthetic Biologics has 17,043,000 shares in issue

What is the market cap of Synthetic Biologics?

The market capitalisation of Synthetic Biologics is USD 17.38M

What is the 1 year trading range for Synthetic Biologics share price?

Synthetic Biologics has traded in the range of US$ 0.00 to US$ 0.00 during the past year

What is the PE ratio of Synthetic Biologics?

The price to earnings ratio of Synthetic Biologics is -1.11

What is the reporting currency for Synthetic Biologics?

Synthetic Biologics reports financial results in USD

What is the latest annual profit for Synthetic Biologics?

The latest annual profit of Synthetic Biologics is USD -18.35M

What is the registered address of Synthetic Biologics?

The registered address for Synthetic Biologics is 9605 MEDICAL CENTER DRIVE, SUITE 270, ROCKVILLE, MARYLAND, 20850

What is the Synthetic Biologics website address?

The website address for Synthetic Biologics is www.syntheticbiologics.com

Which industry sector does Synthetic Biologics operate in?

Synthetic Biologics operates in the BUSINESS SERVICES sector

Symbol	Price	Vol.
AZTRAzitra Inc	US$ 0.4128 (48.22%)	20.31M
ZONECleanCore Solutions Inc	US$ 1.35 (32.34%)	760.36k
PLTYYieldmax Pltr Option Income Strategy ETF	US$ 79.87 (17.82%)	7.88k
KAPAKairos Pharma Ltd	US$ 1.77 (16.45%)	6.62M
GPUSHyperscale Data Inc	US$ 4.40 (14.58%)	96
AWXAvalon Holdngs Corp	US$ 3.05 (-13.30%)	104
ATCHAtlasClear Holdings Inc	US$ 4.00 (-10.71%)	1.38k
BOILProShares Ultra Bloomberg Natural Gas New	US$ 56.40 (-7.93%)	75.84k
FRDFriedman Industries Inc	US$ 14.12 (-7.71%)	6
PMNTPerfect Moment Ltd	US$ 0.742 (-7.25%)	342
AZTRAzitra Inc	US$ 0.4128 (48.22%)	20.31M
KAPAKairos Pharma Ltd	US$ 1.77 (16.45%)	6.62M
ETHU2x Ether ETF	US$ 4.84 (7.08%)	4.23M
SOXLDirexion Daily Semiconductor Bull 3X Shares	US$ 25.83 (0.86%)	1.8M
SOXSDirexion Daily Semiconductor Bear 3X Shares New	US$ 21.49 (-0.83%)	921.33k

Symbol

Price

Vol.

AZTRAzitra Inc

US$ 0.4128

(48.22%)

20.31M

KAPAKairos Pharma Ltd

US$ 1.77

(16.45%)

6.62M

ETHU2x Ether ETF

US$ 4.84

(7.08%)

4.23M

SOXLDirexion Daily Semiconductor Bull 3X Shares

US$ 25.83

(0.86%)

1.8M

SOXSDirexion Daily Semiconductor Bear 3X Shares New

US$ 21.49

(-0.83%)

921.33k

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Synthetic Biologics Inc (SYN)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

About Synthetic Biologics Inc

Ask ADVFN Intelligence (AI)

SYN Latest News

Synthetic Biologics to Present at 2022 BIO CEO & Investor Conference

Synthetic Biologics Announces VCN Biosciences' VCN-01 Receives Orphan Drug Designation for Retinoblastoma from the U.S. FDA

Synthetic Biologics to Present at the B. Riley Securities Oncology Conference on January 28, 2022

Synthetic Biologics Announces Planned Transformative Acquisition of VCN Biosciences; Developer of a Novel Oncolytic Virus Platform Targeting Pancreatic and other Solid Tumors

Synthetic Biologics Reports Third Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET

Synthetic Biologics to Report 2021 Third Quarter Operational Highlights and Financial Results on November 3, 2021

Synthetic Biologics Announces Initiation of a Phase 1 Multiple-Ascending Dose Clinical Trial for SYN-020 Intestinal Alkaline Phosphatase

Synthetic Biologics Announces Second Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

Synthetic Biologics Announces Adjournment of Annual Meeting of Shareholders Due to Lack of Quorum

Synthetic Biologics Reports Second Quarter 2021 Operational Highlights and Financial Results; Conference Call to be Held Today at 4:30 PM ET

SYN - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

Synthetic Biologics Inc (SYN) Share Price

Synthetic Biologics Inc (SYN)

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

About Synthetic Biologics Inc

Ask ADVFN Intelligence (AI)

SYN Latest News

SYN - Frequently Asked Questions (FAQ)

Movers

Discussion

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS